Artivion, Inc. (AORT)
Largest Insider Buys in Sector
AORT Stock Price History Chart
AORT Stock Performance
About Artivion, Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment …
Insider Activity of Artivion, Inc.
Over the last 12 months, insiders at Artivion, Inc. have bought $0 and sold $5.41M worth of Artivion, Inc. stock.
On average, over the past 5 years, insiders at Artivion, Inc. have bought $364,527 and sold $2.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $260,400 was made by SEMEDO ANTHONY B. (director) on 2021‑11‑29.
List of Insider Buy and Sell Transactions, Artivion, Inc.
| 2024-10-01 | Sale | VP, Chief Accounting Officer | 12,430 0.0302% | $26.18 | $325,415 | +1.60% | ||
| 2024-08-26 | Sale | SVP, General Counsel | 3,167 0.0076% | $26.55 | $84,096 | -0.45% | ||
| 2024-08-16 | Sale | VP, Human Resources | 9,420 0.0228% | $25.31 | $238,434 | -0.32% | ||
| 2024-08-15 | Sale | SVP, General Counsel | 2,383 0.0059% | $25.76 | $61,393 | 0.00% | ||
| 2024-08-13 | Sale | director | 9,709 0.0232% | $24.99 | $242,628 | 0.00% | ||
| 2024-05-10 | Sale | SVP, General Counsel | 1,250 0.003% | $23.42 | $29,275 | +8.03% | ||
| 2024-05-09 | Sale | SVP, General Counsel | 979 0.0024% | $23.79 | $23,286 | +8.50% | ||
| 2024-03-20 | Sale | SVP, Clinical & MD Affair | 2,183 0.0052% | $20.39 | $44,511 | +18.82% | ||
| 2024-03-15 | Sale | VP Regulatory | 1,462 0.0036% | $20.00 | $29,240 | +23.23% | ||
| 2024-03-14 | Sale | VP Regulatory | 3,994 0.0097% | $20.00 | $79,880 | +21.20% | ||
| 2024-03-12 | Sale | VP, Human Resources | 5,000 0.0121% | $19.94 | $99,720 | +20.56% | ||
| 2024-03-05 | Sale | President & CEO | 13,996 0.0343% | $18.72 | $262,037 | +28.15% | ||
| 2024-03-05 | Sale | SVP, General Counsel | 2,380 0.0058% | $18.72 | $44,559 | +28.15% | ||
| 2024-03-05 | Sale | Chief Commercial Officer | 2,022 0.005% | $18.72 | $37,856 | +28.15% | ||
| 2024-03-05 | Sale | VP, Chief Accounting Officer | 1,152 0.0028% | $18.72 | $21,568 | +28.15% | ||
| 2024-03-05 | Sale | SVP, Clinical & MD Affair | 1,506 0.0037% | $18.72 | $28,195 | +28.15% | ||
| 2024-03-05 | Sale | VP, Human Resources | 1,157 0.0028% | $18.72 | $21,661 | +28.15% | ||
| 2024-03-05 | Sale | VP Regulatory | 1,160 0.0028% | $18.72 | $21,718 | +28.15% | ||
| 2024-03-05 | Sale | VP, Quality | 1,157 0.0028% | $18.72 | $21,662 | +28.15% | ||
| 2024-03-01 | Sale | SVP, Clinical & MD Affair | 1,506 0.0036% | $18.72 | $28,195 | +24.76% |
Insider Historical Profitability
| Mackin James P | President & CEO | 706038 1.6843% | $28.51 | 4 | 16 | +33.26% |
| Davis John E | Chief Commercial Officer | 165690 0.3953% | $28.51 | 2 | 16 | +28.47% |
| SEMEDO ANTHONY B. | director | 34159 0.0815% | $28.51 | 1 | 1 | +9.19% |
| LEE DAVID ASHLEY | Executive VP, COO & CFO | 347217 0.8283% | $28.51 | 2 | 19 | +25.04% |
| Bullock James | director | 34023 0.0812% | $28.51 | 1 | 0 | +47.76% |
Institutional Investor Ownership
| BlackRock | $142.64M | 16.15 | 6.74M | -1.51% | -$2.19M | <0.01 | |
| Macquarie Group | $59.21M | 6.71 | 2.8M | -2.63% | -$1.6M | 0.05 | |
| Perceptive Advisors | $56.48M | 6.4 | 2.67M | +186.57% | +$36.77M | 0.04 | |
| The Vanguard Group | $56.39M | 6.39 | 2.66M | +1.29% | +$719,059.12 | <0.01 | |
| Morgan Stanley | $49.44M | 5.6 | 2.34M | -1.86% | -$936,478.50 | <0.01 |